Extended Data Fig. 5: ELI-002 2P vaccination amplifies cytotoxic mKRAS-specific CD4+ T cells.
Patients were immunized with 1.4 mg Amph-peptides 2P admixed with 0.1, 0.5, 2.5, 5 or 10 mg of Amph-CpG-7909. PBMCs were collected for T cell response assessment at baseline and week 9 timepoints. a, Shown is the ex vivo mKRAS-specific cytotoxic CD4+ T cell fold change from baseline to week 9 in the extended ICS assay for n = 19 patients. T cell cytotoxic responders are defined as a patient having ≥2-fold increase from baseline at week 9 (dotted line) and >0.1% GrB+ and/or perforin+. b, Pie chart depicts the percentage of tested ELI-002 2P patients that induce CD4+ cytotoxic+ T cells in extended ICS assay. c, Representative flow cytometry plots of PBMCs from patient 11 at baseline and week 9 PBMCs that have been stimulated with OLPs to G12D mKRAS antigen and tested in an ex vivo ICS assay for cytokine and cytotoxic marker production. Shown are CD4+ IL2+ mKRAS-specific T cells that are then gated on granzyme B, perforin and CD45RA and CCR7 memory markers. The frequencies of each population are shown on the dot plots.
